215 related articles for article (PubMed ID: 38611013)
1. Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.
Ayyalasomayajula R; Cudic M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611013
[TBL] [Abstract][Full Text] [Related]
2. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
3. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
4. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
5. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.
Brinkman-Van der Linden EC; Varki A
J Biol Chem; 2000 Mar; 275(12):8625-32. PubMed ID: 10722702
[TBL] [Abstract][Full Text] [Related]
6. Non-canonical roles of Siglecs: Beyond sialic acid-binding and immune cell modulation.
Siddiqui SS
Mol Aspects Med; 2023 Apr; 90():101145. PubMed ID: 36153172
[TBL] [Abstract][Full Text] [Related]
7. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.
Bordoloi D; Kulkarni AJ; Adeniji OS; Pampena MB; Bhojnagarwala PS; Zhao S; Ionescu C; Perales-Puchalt A; Parzych EM; Zhu X; Ali AR; Cassel J; Zhang R; Betts MR; Abdel-Mohsen M; Weiner DB
Sci Adv; 2023 Nov; 9(44):eadh4379. PubMed ID: 37910620
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.
Matsumoto Y; Ju T
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509200
[TBL] [Abstract][Full Text] [Related]
9. Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody.
Fang J; Lai S; Yu H; Ma L
Antibodies (Basel); 2023 Jul; 12(3):. PubMed ID: 37489369
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
11. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE; Joyce JA
Cancer Cell; 2023 Mar; 41(3):374-403. PubMed ID: 36917948
[TBL] [Abstract][Full Text] [Related]
12. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies.
Kapetanakis NI; Busson P
Front Immunol; 2023; 14():1145268. PubMed ID: 36817445
[TBL] [Abstract][Full Text] [Related]
13. Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy.
Franke AK; Wessolowski C; Thaden V; Müller I; Cornils K
Gene Ther; 2023 Aug; 30(7-8):603-611. PubMed ID: 36529796
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
